Cabio Biotech Wuhan Co Ltd

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

0.86

Vol. 1Y

—

Shs. 5Y

-0.12%

Rev. 5Y

11.73%

Div Yld LY

—

Div Yld TTM

—

Revenues

563m

+1.36%

Net income

144m

+15.71%

CFO

270m

+56.07%

Dividend

Jul 10, 20250.20094 /sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Cabio Biotech (Wuhan) Co., Ltd. engages in the research, development, production and sale of polyunsaturated fatty acids and nutrition products. Its products include arachidonic acids (ARA), docosahexaenoic acids (DHA), natural beta-carotene products, infant formula food, functional healthcare food and dietary supplements. The company was founded on September 22, 2004 and is headquartered in Wuhan, China.

URL

http://www.cabio.cn/

IPO date

Dec 19, 2019

Employees

Domiciled in

Incorporated in

Valuation

Latest on right Latest on left

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT